2020
Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness. Clin Case Rep. 2020;8(2):289-292.
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4(20):5226-5231.
Functional impact of cancer patient-associated Bcl-xL mutations. MedComm (Beijing). 2020;1(3):328-337.
DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. Nat Microbiol. 2020;5(8):1051-1063.
Transient commensal clonal interactions can drive tumor metastasis. Nat Commun. 2020;11(1):5799.
Clinical significance of blue-green neutrophil and monocyte cytoplasmic inclusions in SARS-CoV-2 positive critically ill patients. Br J Haematol. 2020;190(2):e89-e92.
CRL4 Ubiquitin Pathway and DNA Damage Response. Adv Exp Med Biol. 2020;1217:225-239.
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020;60:102988.